Cerebrolysin

Cerebrolysin is a porcine-derived peptide mixture, rather than one defined synthetic peptide. The Austrian product information identifies a proteolytic fraction of pig-brain protein at 215.2 mg/mL. Neurotrophic activity is not the same as a verified list of intact human growth factors in the product.

Its clinical research spans stroke rehabilitation, traumatic brain injury and dementia. Those are different conditions with different measures of recovery. Some studies report encouraging findings; others are neutral. The evidence is more useful when read by population and outcome than as a single claim that Cerebrolysin works for brain health.

For U.S. readers, the manufacturer states that its product is not registered with or approved by the FDA for sale or distribution in the United States. A foreign product label does not establish U.S. authorization or make an online product equivalent to the studied medicine. That regulatory context is separate from the scientific findings below.

Cerebrolysin is studied for neurotrophic effects: processes related to neuronal survival, repair and plasticity. Much of the detailed mechanism evidence is preclinical. It should not be read as proof of cognitive enhancement or disease prevention in people.

In a randomized, blinded rat study of closed-head mild traumatic brain injury, researchers assessed tissue and functional outcomes through day 90. Cerebrolysin was associated with less axonal injury and reactive astrocyte change, and more newly generated neurons in the hippocampal dentate gyrus. These findings support research into recovery mechanisms; they do not supply a human treatment protocol.

The product information describes indirect preclinical evidence that components can cross the blood-brain barrier, while noting that direct pharmacokinetic measurement of the mixture is not feasible. That is more limited than saying the entire mixture rapidly reaches a known concentration throughout the human brain.

Stroke rehabilitation: The CARS registry reports 208 randomized patients in a double-blind, placebo-controlled trial. At day 90, the Cerebrolysin group had greater improvement in upper-limb function on the Action Research Arm Test. Treatment was an adjunct to rehabilitation, not a substitute for stroke care.

The preplanned pooled CARS analysis included 442 patients with evaluable data from two trials and favored Cerebrolysin for day-90 arm function. Results differed substantially between the trials, however, and the full-population random-effects sensitivity analysis was not statistically significant. The report discusses milder impairment and ceiling effects in CARS-2 and discloses manufacturer ties.

Acute stroke: In CASTA, 1,070 patients were randomized; the prespecified combined disability and neurological endpoint at day 90 was neutral. Favorable findings in a more severely affected subgroup were post hoc. The 2023 Cochrane review, with searches through June 2022, found little or no mortality benefit for Cerebrolysin or the related agent Cortexin added to standard care. Its acute-stroke question is different from rehabilitation-specific arm recovery.

Traumatic brain injury: The single-center CAPTAIN II trial randomized 142 patients with moderate-to-severe TBI; 139 were analyzed. Cerebrolysin, added to standard care, performed better than placebo on the combined 13-scale outcome at day 90. The original results tables show that individual Glasgow Outcome Scale–Extended, rehabilitation Barthel and Mini-Mental State Examination results were not statistically significant. A favorable combined outcome does not mean every measure improved.

The smaller CAPTAIN I trial enrolled 46 patients with moderate-to-severe TBI. Its combined 14-scale outcome at day 30 did not reach statistical significance in the intention-to-treat analysis, although selected individual tests and the per-protocol analysis favored Cerebrolysin. Together these trials offer an encouraging, but not uniform, recovery signal.

Alzheimer’s disease: A 24-week, placebo-controlled trial randomized 279 patients with mild-to-moderate Alzheimer’s disease to three Cerebrolysin doses or placebo. At week 24, the 10 mL arm showed better cognitive performance; the 30 and 60 mL arms showed global clinical improvement but no statistically significant cognitive benefit. These were clinical-score outcomes, not evidence that the underlying disease was halted or dementia prevented.

Recovery after neurological injury: The most relevant potential benefits are the specific recovery outcomes tested in patients: upper-limb function in CARS rehabilitation research and the multidimensional recovery measure in CAPTAIN II. Neither result establishes a universal benefit across all stroke or TBI outcomes.

Cognitive symptoms in diagnosed disease: The Alzheimer trial gives a reason to investigate symptomatic cognitive and global-function benefit. It does not establish protection from dementia in healthy adults, and more treatment was not consistently better across its dose groups.

Healthy-user experiences: Reports of clearer thinking, improved focus, memory or motivation remain anecdotal. They can inform questions for future research, but cannot separate an actual drug effect from expectation, recovery, sleep changes or other treatments. The patient studies above do not validate those experiences or establish a predictable onset for healthy users.

Keep the routes separate: The named Austrian product permits up to 5 mL IM and up to 10 mL by direct IV administration, recommending infusion from 10 mL. These are product-specific route limits, not a general dose recommendation. An IV amount must not be converted into an IM instruction.

Study exposure is not a maintenance plan: CARS tested 30 mL IV daily for 21 days, starting 24–72 hours after stroke alongside standardized rehabilitation. Different studies used other courses. A supervised stroke trial does not establish an indefinite injection schedule for cognitive enhancement.

Repeat courses and handling: The Austrian label describes repeat courses for dementia, not permanent healthy-user maintenance. It specifies single withdrawal and immediate disposal of unused solution. Store at or below 25°C, protected from light; do not refrigerate or freeze. Follow the applicable product information for clinical administration and preparation.

The Austrian label contraindicates hypersensitivity, status epilepticus and severe renal impairment; other seizure disorders require caution. It flags additive effects with antidepressants or MAOIs. Reported reactions include rare agitation/insomnia and very rare hypersensitivity or seizures. This is not an interaction-free product.

The CARS pooled report recorded serious adverse events in 4.9% of each group, without investigator attribution to treatment. In contrast, the acute-stroke Cochrane review found a probable increase in nonfatal serious adverse events with Cerebrolysin, despite little or no difference in serious events overall. Different populations and outcomes need to remain separate.

The CAPTAIN II registry also records serious events, including deaths, with causality assessed as unlikely or unrelated. That is not the same as saying no serious events occurred. Trial observations cannot establish indefinite safety, guaranteed absence of tolerance or withdrawal, or superiority to every alternative.

The label does not recommend use under 18 because data are insufficient. Pregnancy requires clinical necessity; breastfeeding requires a treatment-versus-feeding decision. These points support an individual clinical assessment, not a blanket assurance across all patient groups.